Role of antiviral therapy in the prevention of hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 9 II, 2002, Pages

  Franco, Jose ^a   Saeian, Kia ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Antiviral therapy; Liver neoplasms, therapy

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPLASIA; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEROCONVERSION; VIRUS RESISTANCE;

EID: 0036741737     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1051-0443(07)61786-2     Document Type: Review

References (41)

1. Moriya K, Fuje H, Shintani Y, et al. The core protein of hepatitis CV virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065-1067.
2. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J of Cellular Physiology 1999; 181:188-202.
3. Fowler MJF, Greenfield C, Chu CM, et al. Integration of HBV DNA may not be a prerequisite for the maintenance of the state of malignant transformation. J Hepatol 1986; 2:218-229.
4. Shimada M, Rikimaru T, Sugimachi, K, et al. The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver. J Am Coll Surg 2000; 191:531-537.
5. Bralet M, Regimbeau J, Pineau P, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000; 32:200-204.
6. Chang MH, Shau WY, Chen CJ, et al. The Taiwan Childhood Hepatoma Study Group: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284:3040-3042.
7. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-782.
8. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321:1501-1506.
9. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989;321:1506-10.
10. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
11. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
12. Merle P, Chevallier M, Levy R, et al. Preliminary results of interferon-α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice. J Hepatol 2001; 34:562-569.
13. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1380.
14. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
15. Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29:1870-1875.
16. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83:901-909.
17. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33:1299-1302.
18. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-1130.
19. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-181.
20. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1,148 patients-Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30:653-659.
21. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C: Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129:94-99.
22. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C: Osaka Liver Disease Study Group. Hepatology 1998; 27:1394-1402.
23. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective study. Lancet 1998; 351:1535-1539.
24. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-1440.
25. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C: European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27:201-205.
26. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-758.
27. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141-147.
28. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31(suppl):S137-142.
29. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82:827-835.
30. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis Be antigen-positive patients with compensated cirrhosis treated with interferon alfa: European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26:1338-1342.
31. Wong JB, Koff RS, Ine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis Be antigen-positive hepatitis B. Ann Intern Med 1995; 122:664-675.
32. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-1666.
33. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
34. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
35. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
36. Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 349:3-4.
37. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-568.
38. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2000 49:436-440.
39. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34:578-582.
40. Lai CL, Lau JYN, Wu PC, et al. Recombinant interferon-α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-394.
41. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001; 134:963-967.